Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The American Journal of the Medical Sciences
|
August 6, 2011
Cocaine-induced thrombotic vasculopathy
Seby John, Sudhir Manda, David Hamrock
Investigational New Drugs
|
December 10, 2009
Temporal evolution of patient characteristics enrolled on phase I trials
Afshin Dowlati, Madappa Kundranda, Sudhir Manda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Multi-institutional phase I trials of anticancer agents
Afshin Dowlati, Sudhir Manda, Joseph Gibbons, et al.
Investigational New Drugs
|
September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
Charles J Nock, Joanna M Brell, Joseph A Bokar, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Cancer
|
May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
Max J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Ejhaem
|
June 9, 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Barry Paul, Jiri Minarik, Francesca Cottini, et al.
Hematological Oncology
|
May 7, 2024
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
Sudhir Manda, Bertrand M Anz, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
Sudhir Manda, Habte A Yimer, Stephen J Noga, et al.
The Lancet. Haematology
|
November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The American Journal of the Medical Sciences
|
August 6, 2011
Cocaine-induced thrombotic vasculopathy
Seby John, Sudhir Manda, David Hamrock
Investigational New Drugs
|
December 10, 2009
Temporal evolution of patient characteristics enrolled on phase I trials
Afshin Dowlati, Madappa Kundranda, Sudhir Manda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Multi-institutional phase I trials of anticancer agents
Afshin Dowlati, Sudhir Manda, Joseph Gibbons, et al.
Investigational New Drugs
|
September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
Charles J Nock, Joanna M Brell, Joseph A Bokar, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Cancer
|
May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
Max J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Ejhaem
|
June 9, 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Barry Paul, Jiri Minarik, Francesca Cottini, et al.
Hematological Oncology
|
May 7, 2024
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
Sudhir Manda, Bertrand M Anz, Christopher Benton, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
Sudhir Manda, Habte A Yimer, Stephen J Noga, et al.
The Lancet. Haematology
|
November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Page
of 1